Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 94Esophageal Neoplasms 88Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Neoplasms 42Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Adenocarcinoma 30Gastrointestinal Neoplasms 29Liver Neoplasms 25Esophageal Squamous Cell Carcinoma 23Carcinoma, Non-Small-Cell Lung 18Bile Duct Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Locally Advanced Rectal Cancer 13Colorectal Cancer Metastatic 11Appendiceal Neoplasms 11Recurrence 10Peritoneal Neoplasms 10Ovarian Neoplasms 9Carcinoma 7Breast Neoplasms 7Neurotoxicity Syndromes 6Gastrointestinal Diseases 6

Interventions

Trastuzumab 5Oxaliplatin 4Capecitabine 3trastuzumab deruxtecan 2tislelizumab 2disitamab vedotin 2Tegafur 2Fluorouracil 2Cisplatin 2tucatinib 1pembrolizumab 1S 1 (combination) 1Ramucirumab 1Paclitaxel 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Oxaliplatin × Gastrointestinal × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
153 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡